Skip to main navigation

About
- Team
- Contact
Research & Development
Pipeline
- RMC-4630
- Mutant RAS
- SOS1
- RMC-5552
Investors
Careers

Press Releases

Press Releases

Year

January 13, 2020

Revolution Medicines Presents Data from its SHP2 and Oncogenic RAS(ON) Programs at 6th AACR-IASLC International Joint Conference

January 7, 2020

Revolution Medicines to Present Preliminary Data from Phase 1 Clinical Trial of RMC-4630 at 6th AACR-IASLC International Joint Conference

November 4, 2019

Revolution Medicines and Amgen Partner on Phase 1b Study to Evaluate Combination of RMC-4630 and AMG 510

October 22, 2019

Revolution Medicines to Present Preclinical Data on Novel Inhibitors of Oncogenic RAS(ON) Mutants at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 17, 2019

REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor

July 9, 2019

REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers

January 3, 2019

REVOLUTION Medicines to Present at the J.P. Morgan Healthcare Conference on January 8, 2019

November 13, 2018

REVOLUTION Medicines Announces Presentations at Scientific Meetings in Third and Fourth Quarters of 2018

October 16, 2018

REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets

October 9, 2018

REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Next page
Last page

Displaying 31 - 40 of 54

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2021 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063

Search Investor Relations